Post-hoc analysis of 312 diabetic and 1957 non-diabetic gout patients [ baseline serum urate levels ( sUA ) 8.0 mg/dl ] enrolled in a 6-month randomized controlled trial comparing urate-lowering efficacy ( ULE ) and safety of daily xanthine oxidase inhibitors ( XOIs ) febuxostat ( 40mg or 80mg ) and allopurinol ( 200mg or 300mg ) .
